BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Oliveira LH, Camacho LA, Coutinho ES, Martinez-Silveira MS, Carvalho AF, Ruiz-Matus C, Toscano CM. Impact and Effectiveness of 10 and 13-Valent Pneumococcal Conjugate Vaccines on Hospitalization and Mortality in Children Aged Less than 5 Years in Latin American Countries: A Systematic Review. PLoS One 2016;11:e0166736. [PMID: 27941979 DOI: 10.1371/journal.pone.0166736] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 12.2] [Reference Citation Analysis]
Number Citing Articles
1 Bodin J, Mihret A, Holm-Hansen C, Dembinski JL, Trieu MC, Tessema B, Tarekegne A, Yimer SA, Cox R, Aseffa A, Haneberg B, Mjaaland S. Vitamin D Deficiency is Associated with Increased Use of Antimicrobials among Preschool Girls in Ethiopia. Nutrients 2019;11:E575. [PMID: 30866564 DOI: 10.3390/nu11030575] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Gutiérrez-Tobar IF, Londoño-Ruiz JP, Mariño-Drews C, Beltrán-Higuera S, Camacho-Moreno G, Leal-Castro AL, Patiño-Niño JA, Álvarez-Olmos MI, Barrero-Barreto R, Espinosa F, Suarez MA, Ramos N, Moreno-Mejia VM, Marín A, Sierra Parada CR, Pescador A, Montañez A. Epidemiological characteristics and serotype distribution of culture-confirmed pediatric pneumococcal pneumonia before and after PCV 10 introduction, a multicenter study in Bogota, Colombia, 2008-2019. Vaccine 2022:S0264-410X(22)00299-7. [PMID: 35396166 DOI: 10.1016/j.vaccine.2022.03.022] [Reference Citation Analysis]
3 Jimbo Sotomayor R, Toscano CM, Sánchez Choez X, Vilema Ortíz M, Rivas Condo J, Ghisays G, Haneuse S, Weinberger DM, McGee G, de Oliveira LH. Impact of pneumococcal conjugate vaccine on pneumonia hospitalization and mortality in children and elderly in Ecuador: Time series analyses. Vaccine 2020;38:7033-9. [PMID: 32981782 DOI: 10.1016/j.vaccine.2020.09.032] [Reference Citation Analysis]
4 Oligbu G, Collins S, Djennad A, Sheppard CL, Fry NK, Andrews NJ, Borrow R, Ramsay ME, Ladhani SN. Effect of Pneumococcal Conjugate Vaccines on Pneumococcal Meningitis, England and Wales, July 1, 2000-June 30, 2016. Emerg Infect Dis 2019;25:1708-18. [PMID: 31441745 DOI: 10.3201/eid2509.180747] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
5 Ngocho JS, Magoma B, Olomi GA, Mahande MJ, Msuya SE, de Jonge MI, Mmbaga BT. Effectiveness of pneumococcal conjugate vaccines against invasive pneumococcal disease among children under five years of age in Africa: A systematic review. PLoS One 2019;14:e0212295. [PMID: 30779801 DOI: 10.1371/journal.pone.0212295] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
6 Isturiz R, Sings HL, Hilton B, Arguedas A, Reinert R, Jodar L. Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert Review of Vaccines 2017;16:1007-27. [DOI: 10.1080/14760584.2017.1362339] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 12.6] [Reference Citation Analysis]
7 Tomczyk S, Lessa FC, Sánchez J, Peña C, Fernández J, Gloria Carvalho M, Pimenta F, Cedano D, Whitney CG, Verani JR, Coradin H, Garib Z, De Oliveira LH, Feris-Iglesias J. Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic. BMC Infect Dis 2018;18:152. [PMID: 29609548 DOI: 10.1186/s12879-018-3047-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Carmona Martinez A, Prymula R, Miranda Valdivieso M, Otero Reigada MDC, Merino Arribas JM, Brzostek J, Szenborn L, Ruzkova R, Horn MR, Jackowska T, Centeno-Malfaz F, Traskine M, Dobbelaere K, Borys D. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study. Vaccine 2019;37:176-86. [PMID: 30054160 DOI: 10.1016/j.vaccine.2018.07.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
9 Ahmed SS, Lessa FC, Coradin H, Sánchez J, Carvalho MDG, Soda E, Peña C, Fernández J, Cedano D, Whitney CG, Feris-Iglesias J. High Prevalence of Vaccine-Type Infections Among Children with Pneumococcal Pneumonia and Effusion After 13-Valent Pneumococcal Conjugate Vaccine Introduction in the Dominican Republic. J Infect Dis 2021;224:S228-36. [PMID: 34469563 DOI: 10.1093/infdis/jiab134] [Reference Citation Analysis]
10 Gomez J, Moreno LE, Constenla D, Caceres D, Rodriguez E. Budget impact analysis of pneumococcal conjugate vaccines in Colombia. Expert Rev Pharmacoecon Outcomes Res 2021;21:255-63. [PMID: 33249948 DOI: 10.1080/14737167.2021.1855978] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Johansson Kostenniemi U, Norman D, Sellin M, Silfverdal SA. Sustained reductions of invasive infectious disease following general infant Haemophilus influenzae type b and pneumococcal vaccination in a Swedish Arctic region. Acta Paediatr 2019;108:1871-8. [PMID: 31025393 DOI: 10.1111/apa.14824] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
12 Reyes JM, LaRotta J, Castano N, Fletcher MA, Wasserman M, Perdrizet J, Sini de Almeida R. Letter to the editor regarding "Budget impact analysis of pneumococcal conjugate vaccines in Colombia". Expert Rev Pharmacoecon Outcomes Res 2021;:1-3. [PMID: 34569403 DOI: 10.1080/14737167.2022.1986006] [Reference Citation Analysis]
13 Reyburn R, Nand D, Nguyen C, Naidu S, Bali A, Rokovutoro M, Ratu T, Kumar S, Lewis D, Smith V, Russell F. Validation of administrative data to estimate vaccine impact: Audit of the Fiji hospital admissions electronic database, 2007–2011 & 2014–2015. Vaccine 2017;35:6416-21. [DOI: 10.1016/j.vaccine.2017.09.091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
14 Marom T, Shemesh S, Habashi N, Gluck O, Tamir SO. Adult Otogenic Meningitis in the Pneumococcal Conjugated Vaccines Era. Int Arch Otorhinolaryngol 2020;24:e175-81. [PMID: 32256838 DOI: 10.1055/s-0039-1697995] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Lagoubi Y, Sfar MT, Gomez JA. A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia. Hum Vaccin Immunother 2022;:2079305. [PMID: 35703731 DOI: 10.1080/21645515.2022.2079305] [Reference Citation Analysis]
16 Caceres DC, Ortega-Barria E, Nieto J, DeAntonio R. Pneumococcal meningitis trends after pneumococcal conjugate vaccine introduction in Colombia: An interrupted time-series analysis. Hum Vaccin Immunother 2018;14:1230-3. [PMID: 29351491 DOI: 10.1080/21645515.2018.1425115] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Camargos P, Nascimento-carvalho CM, Teixeira R, França E. Lower respiratory infections mortality among Brazilians under-five before and after national pneumococcal conjugate vaccine implementation. Vaccine 2020;38:2559-65. [DOI: 10.1016/j.vaccine.2020.01.084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Esposito S, Principi N. Pneumococcal immunization with conjugate vaccines: are 10-valent and 13-valent vaccines similar? Future Microbiol 2019;14:921-3. [PMID: 31373218 DOI: 10.2217/fmb-2019-0151] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
19 Tan KK, Dang DA, Kim KH, Kartasasmita C, Kim HM, Zhang XH, Shafi F, Yu TW, Ledesma E, Meyer N. Burden of hospitalized childhood community-acquired pneumonia: A retrospective cross-sectional study in Vietnam, Malaysia, Indonesia and the Republic of Korea. Hum Vaccin Immunother 2018;14:95-105. [PMID: 29125809 DOI: 10.1080/21645515.2017.1375073] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
20 Horn M, Behre U, Traskine M, Dobbelaere K, Borys D. Safety, reactogenicity, and immunogenicity of a 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine in healthy toddlers: results from a phase I, randomized trial. Hum Vaccin Immunother 2021;17:1463-9. [PMID: 33175600 DOI: 10.1080/21645515.2020.1810493] [Reference Citation Analysis]
21 Gómez JA, Guzman Holst A, Nieto J. Response to article by Matthew Wasserman et al. (2018): "Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico". Hum Vaccin Immunother 2019;15:570-1. [PMID: 30570428 DOI: 10.1080/21645515.2018.1554974] [Reference Citation Analysis]
22 Castiglia P, Pradelli L, Castagna S, Freguglia V, Palù G, Esposito S. Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy. Hum Vaccin Immunother 2017;13:2307-15. [PMID: 28700264 DOI: 10.1080/21645515.2017.1343773] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
23 Reyburn R, Tuivaga EJ, Ratu FT, Dunne EM, Nand D, Kado J, Jenkins K, Tikoduadua L, Jenney A, Howden BP, Ballard SA, Fox K, Devi R, Satzke C, Rafai E, Kama M, Flasche S, Mulholland EK, Russell FM. The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji. Lancet Reg Health West Pac 2022;20:100352. [PMID: 35028629 DOI: 10.1016/j.lanwpc.2021.100352] [Reference Citation Analysis]
24 Lu CY, Tang CH, Fu T, Pwu RF, Ho YF. Pneumococcal conjugate vaccines in Taiwan: optimizing health gains in children and older adults through constrained optimization modeling: Pneumococcal conjugate vaccines optimization in Taiwan. Int J Infect Dis 2021;114:155-64. [PMID: 34749009 DOI: 10.1016/j.ijid.2021.10.058] [Reference Citation Analysis]
25 Sigurdsson S, Eythorsson E, Erlendsdóttir H, Hrafnkelsson B, Kristinsson KG, Haraldsson Á. Impact of the 10-valent pneumococcal conjugate vaccine on hospital admissions in children under three years of age in Iceland. Vaccine 2020;38:2707-14. [PMID: 32063434 DOI: 10.1016/j.vaccine.2020.01.094] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Nieto Guevara J, Borys D, DeAntonio R, Guzman-Holst A, Hoet B. Interchangeability between pneumococcal conjugate vaccines for pediatric use: a systematic literature review. Expert Rev Vaccines 2020;19:1011-22. [PMID: 31751159 DOI: 10.1080/14760584.2019.1688148] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Gomez JA, Caceres D, Rodriguez E. Budget impact analysis of pneumococcal conjugate vaccines in Colombia. Response to letter to the editor. Expert Rev Pharmacoecon Outcomes Res 2021;:1-2. [PMID: 34612137 DOI: 10.1080/14737167.2022.1986007] [Reference Citation Analysis]
28 Mpabalwani EM, Lukwesa-Musyani C, Imamba A, Nakazwe R, Matapo B, Muzongwe CM, Mufune T, Soda E, Mwenda JM, Lutz CS, Pondo T, Lessa FC. Declines in Pneumonia and Meningitis Hospitalizations in Children Under 5 Years of Age After Introduction of 10-Valent Pneumococcal Conjugate Vaccine in Zambia, 2010-2016. Clin Infect Dis 2019;69:S58-65. [PMID: 31505628 DOI: 10.1093/cid/ciz456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Mungall BA, Nieto J, Soumahoro L, Hoet B. Letter to the editor to: Isturiz et al. Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert review of vaccines 2017;16(10):1007-27. Expert Rev Vaccines 2018;17:665-8. [PMID: 30067110 DOI: 10.1080/14760584.2018.1506205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 de Los Santos AM, Rodríguez-Weber MA, Sánchez-Márquez P, Traskine M, Carreño-Manjarrez R, Cervantes-Apolinar MY, Strezova A, Ruiz-Guiñazú J, Ortega-Barria E, Borys D. Can two different pneumococcal conjugate vaccines be used to complete the infant vaccination series? A randomized trial exploring interchangeability of the 13-valent pneumococcal conjugate vaccine and the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine. Expert Rev Vaccines 2020;19:995-1010. [PMID: 33297773 DOI: 10.1080/14760584.2020.1843431] [Reference Citation Analysis]
31 Ikken Y, Charof R, Benaouda A, Hilali F, Akkaoui S, Elouennass M, Sekhsokh Y. Epidemiology and antibiotic resistance profile of bacterial meningitis in Morocco from 2015 to 2018. Acta Microbiol Immunol Hung 2020;67:243-51. [PMID: 33221736 DOI: 10.1556/030.2020.01222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
32 Talathi S, Gupta N, Sethuram S, Khanna S, Sitnitskaya Y. Otitis Media in Fully Vaccinated Preschool Children in the Pneumococcal Conjugate Vaccine Era. Glob Pediatr Health 2017;4:2333794X17749668. [PMID: 29308427 DOI: 10.1177/2333794X17749668] [Reference Citation Analysis]
33 de Oliveira LH, Shioda K, Valenzuela MT, Janusz CB, Rearte A, Sbarra AN, Warren JL, Toscano CM, Weinberger DM; Multinational Study for PCV Impact in Mortality Study Team. Declines in Pneumonia Mortality Following the Introduction of Pneumococcal Conjugate Vaccines in Latin American and Caribbean Countries. Clin Infect Dis 2021;73:306-13. [PMID: 32448889 DOI: 10.1093/cid/ciaa614] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
34 Cohen R, Cohen JF, Chalumeau M, Levy C. Impact of pneumococcal conjugate vaccines for children in high- and non–high-income countries. Expert Review of Vaccines 2017;16:625-40. [DOI: 10.1080/14760584.2017.1320221] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
35 Hammitt LL, Etyang AO, Morpeth SC, Ojal J, Mutuku A, Mturi N, Moisi JC, Adetifa IM, Karani A, Akech DO, Otiende M, Bwanaali T, Wafula J, Mataza C, Mumbo E, Tabu C, Knoll MD, Bauni E, Marsh K, Williams TN, Kamau T, Sharif SK, Levine OS, Scott JAG. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study. Lancet 2019;393:2146-54. [PMID: 31000194 DOI: 10.1016/S0140-6736(18)33005-8] [Cited by in Crossref: 56] [Cited by in F6Publishing: 28] [Article Influence: 18.7] [Reference Citation Analysis]
36 Jimbo-Sotomayor R, Armijos-Acurio L, Proaño-Espinosa J, Segarra-Galarza K, Sánchez-Choez X. Morbidity and Mortality Due to Pneumococcal Disease in Children in Ecuador from 2005 to 2015. J Glob Infect Dis 2020;12:124-8. [PMID: 33343162 DOI: 10.4103/jgid.jgid_125_19] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Toscano CM, Suarez V, Michel F, Bierrenbach AL, Gonzales M, Alencar AP, Ruiz Matus C, Andrus JK, de Oliveira LH. Response to comment on: Impact of pneumococcal conjugate vaccine in children morbidity and mortality in Peru: Time series analyses. Vaccine 2017;35:4826-7. [PMID: 28838424 DOI: 10.1016/j.vaccine.2017.03.105] [Reference Citation Analysis]
38 Gomez JA, Lopes de Abreu AJ, Caceres DC, Nieto J, Ortega-Barria E. Estimated Annual Health and Cost Impact of PHiD-CV Immunization Program in Brazil. Pediatr Infect Dis J 2019;38:e260-5. [PMID: 31568144 DOI: 10.1097/INF.0000000000002436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
39 Jimbo-Sotomayor R, Watts E, Armijos L, Sriudomporn S, Sánchez X, Echeverria A, Whittembury A, Patenaude B. Return on Investment of 10-Valent Pneumococcal Conjugate Vaccine in Ecuador From 2010 to 2030. Value Health Reg Issues 2022;31:148-54. [PMID: 35753214 DOI: 10.1016/j.vhri.2022.05.003] [Reference Citation Analysis]
40 Obi-Jeff C, Rakhshani NS, Bello-Malabu JI, Nwangwu C, Nwaononiwu E, Eboreime E, Wonodi C. Vaccine indicator and reminder band to improve demand for vaccination in Northern Nigeria: A qualitative evaluation of implementation outcomes. Vaccine 2020;38:4191-9. [PMID: 32376107 DOI: 10.1016/j.vaccine.2020.04.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Wang Q, Shi W, Li Y, Gao W, Yuan L, Dong F, Yao K. Serotype distribution of Streptococcus pneumoniae isolated from children hospitalized in Beijing children's hospital (2013-2019). Vaccine 2020;38:7858-64. [PMID: 33164807 DOI: 10.1016/j.vaccine.2020.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Schuck-Paim C, Taylor RJ, Alonso WJ, Weinberger DM, Simonsen L. Effect of pneumococcal conjugate vaccine introduction on childhood pneumonia mortality in Brazil: a retrospective observational study. Lancet Glob Health 2019;7:e249-56. [PMID: 30683242 DOI: 10.1016/S2214-109X(18)30455-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 12.5] [Reference Citation Analysis]
43 Suwantika AA, Zakiyah N, Abdulah R, Sitohang V, Tandy G, Anartati A, Hidayatullah T, Herliana P, Hadinegoro SR. Cost-Effectiveness and Budget Impact Analyses of Pneumococcal Vaccination in Indonesia. J Environ Public Health 2021;2021:7494965. [PMID: 33995536 DOI: 10.1155/2021/7494965] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Reyburn R, Tuivaga E, Nguyen CD, Ratu FT, Nand D, Kado J, Tikoduadua L, Jenkins K, de Campo M, Kama M, Devi R, Rafai E, Weinberger DM, Mulholland EK, Russell FM. Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumonia hospital admissions in Fiji: a time-series analysis. Lancet Glob Health 2021;9:e91-8. [PMID: 33227258 DOI: 10.1016/S2214-109X(20)30421-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
45 Scotta MC, Marostica PJ, Stein RT. Pneumonia in Children. Kendig's Disorders of the Respiratory Tract in Children. Elsevier; 2019. pp. 427-438.e4. [DOI: 10.1016/b978-0-323-44887-1.00025-0] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 Marijam A, Olbrecht J, Ozakay A, Eken V, Meszaros K. Cost-Effectiveness Comparison of Pneumococcal Conjugate Vaccines in Turkish Children. Value Health Reg Issues 2019;19:34-44. [PMID: 30776766 DOI: 10.1016/j.vhri.2018.11.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
47 Suwantika AA, Zakiyah N, Kusuma ASW, Abdulah R, Postma MJ. Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia. Vaccines (Basel) 2020;8:E233. [PMID: 32443523 DOI: 10.3390/vaccines8020233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
48 Bierrenbach AL, Minamisava R, Alencar AP, Alencar GP, Andrade AL. Combined effect of PCV10 and meningococcal C conjugate vaccination on meningitis mortality among children under five years of age in Brazil. Hum Vaccin Immunother 2018;14:1138-45. [PMID: 29068749 DOI: 10.1080/21645515.2017.1391431] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
49 Gomez JA, Guevara JN, Carlos JC, de Castro JA, Josue DR, Rodriguez E. Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”. Infect Dis Ther. [DOI: 10.1007/s40121-022-00640-w] [Reference Citation Analysis]
50 Gómez JA, Pinto TJP, Guevara JN, Noronha TG. Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants". Hum Vaccin Immunother 2021;:1-3. [PMID: 34010099 DOI: 10.1080/21645515.2021.1894898] [Reference Citation Analysis]
51 Mungall BA, Hoet B, Nieto Guevara J, Soumahoro L. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. Expert Rev Vaccines 2021. [PMID: 34882050 DOI: 10.1080/14760584.2022.2012455] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 McGirr A, Iqbal SM, Olbrecht J, Varghese L. Comment on: 'Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada', Wilson et al., 22 June 2018. Infect Dis Ther 2018;7:535-8. [PMID: 30411202 DOI: 10.1007/s40121-018-0220-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Whitney CG, Toscano CM. Direct effects of pneumococcal conjugate vaccines among children in Latin America and the Caribbean. Lancet Infect Dis 2021;21:306-8. [PMID: 32986995 DOI: 10.1016/S1473-3099(20)30511-9] [Reference Citation Analysis]
54 Fu J, Yi R, Jiang Y, Xu S, Qin P, Liang Z, Chen J. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae causing invasive diseases in China: a meta-analysis. BMC Pediatr 2019;19:424. [PMID: 31711442 DOI: 10.1186/s12887-019-1722-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
55 Izurieta P, AbdelGhany M, Paynter J, Petousis-Harris H. Recommendation to take a holistic view of the dynamic pathogenic pneumococcal environment. Clin Infect Dis 2022:ciac188. [PMID: 35274677 DOI: 10.1093/cid/ciac188] [Reference Citation Analysis]
56 Nieto Guevara J, Izurieta P. Reply to 'Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in Bogotá, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10'. Hum Vaccin Immunother 2020;16:2307-8. [PMID: 32643508 DOI: 10.1080/21645515.2020.1784654] [Reference Citation Analysis]
57 Chacon-Cruz E, Roberts C, Rivas-Landeros RM, Lopatynsky-Reyes EZ, Almada-Salazar LA, Alvelais-Palacios JA. Pediatric meningitis due to Neisseria meningitidis, Streptococcus pneumoniae and Group B Streptococcus in Tijuana, Mexico: active/prospective surveillance, 2005-2018. Ther Adv Infect Dis 2019;6:2049936119832274. [PMID: 30886712 DOI: 10.1177/2049936119832274] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Lourenço J, Daon Y, Gori A, Obolski U. Pneumococcal Competition Modulates Antibiotic Resistance in the Pre-Vaccination Era: A Modelling Study. Vaccines (Basel) 2021;9:265. [PMID: 33809706 DOI: 10.3390/vaccines9030265] [Reference Citation Analysis]
59 Dondo V, Mujuru H, Nathoo K, Jacha V, Tapfumanei O, Chirisa P, Manangazira P, Macharaga J, de Gouveia L, Mwenda JM, Katsande R, Weldegebriel G, Pondo T, Matanock A, Lessa FC. Pneumococcal Conjugate Vaccine Impact on Meningitis and Pneumonia Among Children Aged <5 Years-Zimbabwe, 2010-2016. Clin Infect Dis 2019;69:S72-80. [PMID: 31505631 DOI: 10.1093/cid/ciz462] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Severiche-Bueno DF, Severiche-Bueno DF, Bastidas A, Caceres EL, Silva E, Lozada J, Gomez S, Vargas H, Viasus D, Reyes LF. Burden of invasive pneumococcal disease (IPD) over a 10-year period in Bogotá, Colombia. Int J Infect Dis 2021;105:32-9. [PMID: 33582374 DOI: 10.1016/j.ijid.2021.02.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
61 Alvarado S, Cavada G, Villena R, Wilhelm J, Budnik I, Lara C, Salinas X, Azpilcueta N, Valenzuela MT. [Impact of the 10-valent pneumococcal conjugate vaccine on the southern area of Santiago (Chile), 2009-2015Efeito da vacina pneumocócica 10-valente conjugada na região sul de Santiago, Chile, 2009-2015]. Rev Panam Salud Publica 2018;42:e155. [PMID: 31093183 DOI: 10.26633/RPSP.2018.155] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
62 Izurieta P, Scherbakov M, Nieto Guevara J, Vetter V, Soumahoro L. Systematic review of the efficacy, effectiveness and impact of high-valency pneumococcal conjugate vaccines on otitis media. Hum Vaccin Immunother 2022;:1-18. [PMID: 35020530 DOI: 10.1080/21645515.2021.2013693] [Reference Citation Analysis]
63 Odutola A, Ota MOC, Antonio M, Ogundare EO, Saidu Y, Owiafe PK, Worwui A, Idoko OT, Owolabi O, Kampmann B, Greenwood BM, Alderson M, Traskine M, Swinnen K, Verlant V, Dobbelaere K, Borys D. Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants. Vaccine 2019;37:2586-99. [PMID: 30975570 DOI: 10.1016/j.vaccine.2019.03.033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
64 Toscano CM, Valenzuela MT, Martinez-silveira MS, Quarti M, da Costa Oliveira MT, de Oliveira LH. Bacterial etiology of pneumonia in children up to 2 months of age: a systematic review. Gates Open Res 2022;6:15. [DOI: 10.12688/gatesopenres.13576.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Carrasquilla G, Porras-Ramírez A, Martinez S, DeAntonio R, Devadiga R, Talarico C, Caceres DC, Castrejon MM, Juliao P. Trends in all-cause pneumonia and otitis media in children aged <2 years following pneumococcal conjugate vaccine introduction in Colombia. Hum Vaccin Immunother 2021;17:1173-80. [PMID: 32966144 DOI: 10.1080/21645515.2020.1805990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Alicino C, Paganino C, Orsi A, Astengo M, Trucchi C, Icardi G, Ansaldi F. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: A systematic review and meta-analysis. Vaccine 2017;35:5776-85. [DOI: 10.1016/j.vaccine.2017.09.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
67 Ben-Shimol S, Givon-Lavi N, Kotler L, Adriaan van der Beek B, Greenberg D, Dagan R. Post-13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines. Emerg Infect Dis 2021;27:150-60. [PMID: 33350916 DOI: 10.3201/eid2701.201178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
68 Varghese L, Talbot L, Govender A, Zhang XH, Mungall BA. A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand. Appl Health Econ Health Policy 2018;16:331-45. [PMID: 29633160 DOI: 10.1007/s40258-018-0387-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Agudelo CI, Deantonio R, Castañeda E. Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean 2010–2015: A systematic review and a time series analysis. Vaccine 2018;36:4861-74. [DOI: 10.1016/j.vaccine.2018.06.068] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
70 Zhu X, Li X. Pneumococcal vaccine effect on hospitalisation rates of pneumonia in children: A meta-analysis. Int J Clin Pract 2021;:e14739. [PMID: 34388857 DOI: 10.1111/ijcp.14739] [Reference Citation Analysis]
71 Wasserman M, Palacios MG, Grajales AG, Wilson M, McDade C, Farkouh R. Comment on Gomez et. al. "Response to article by Wasserman et. al. (2018) 'Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico'". Hum Vaccin Immunother 2019;15:572-4. [PMID: 30657407 DOI: 10.1080/21645515.2018.1558691] [Reference Citation Analysis]
72 Izurieta P, Nieto Guevara J. Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease. Hum Vaccin Immunother 2021;:1-8. [PMID: 33605846 DOI: 10.1080/21645515.2021.1872341] [Reference Citation Analysis]
73 Lu CY, Chung CH, Huang LM, Kruger E, Tan SC, Zhang XH, Chiu NC. Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan. Cost Eff Resour Alloc 2020;18:30. [PMID: 32874139 DOI: 10.1186/s12962-020-00225-9] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 McGirr A, Iqbal SM, Izurieta P, Talarico C, Luijken J, Redig J, Newson RS. A systematic literature review and network meta-analysis feasibility study to assess the comparative efficacy and comparative effectiveness of pneumococcal conjugate vaccines. Hum Vaccin Immunother 2019;15:2713-24. [PMID: 31216216 DOI: 10.1080/21645515.2019.1612667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
75 Besnier E, Thomson K, Stonkute D, Mohammad T, Akhter N, Todd A, Rom Jensen M, Kilvik A, Bambra C. Which public health interventions are effective in reducing morbidity, mortality and health inequalities from infectious diseases amongst children in low- and middle-income countries (LMICs): An umbrella review. PLoS One 2021;16:e0251905. [PMID: 34111134 DOI: 10.1371/journal.pone.0251905] [Reference Citation Analysis]
76 Lecrenier N, Marijam A, Olbrecht J, Soumahoro L, Nieto Guevara J, Mungall B. Ten years of experience with the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine ( Synflorix ) in children. Expert Review of Vaccines 2020;19:247-65. [DOI: 10.1080/14760584.2020.1738226] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
77 Izurieta P, Bahety P, Adegbola R, Clarke C, Hoet B. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution. Expert Review of Vaccines 2018;17:479-93. [DOI: 10.1080/14760584.2018.1413354] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
78 Mrkvan T, Pelton SI, Ruiz-Guiñazú J, Palmu AA, Borys D. Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience. Expert Rev Vaccines 2018;17:797-818. [PMID: 30185083 DOI: 10.1080/14760584.2018.1516551] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]